Have you been diagnosed with Low Risk Breast Cancer? Have you already been treated with surgery? If so, you may be able to take part in a research study looking at the effect of regional nodal radiotherapy.

This is a clinical research study for people with Stage 4 lung cancer or lung cancer that has returned after treatment. In this study, we want to learn if treatment with two study drugs (ramucirumab and pembrolizumab) works better than usual treatment.

Do you have small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC)? Has your lung cancer come back or did not get better with the last treatment you were given? If so, you may be able to take part in a gene therapy research study that uses your own modified immune cells as treatment.

Pancreatic cancer has one of the lowest survival rates for all cancers, but there are some people who achieve long-term survival. We are looking at those patients, with the goal of identifying what are some treatments and experiences that do work. Learning about treatment combinations and unique therapies that have led to success can open doors for where our research should be focused moving forward.

Do you have Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia? Are you looking for other treatment options? We are doing a study to find out whether treatment with the study drug (Bexmarilimab) along with standard treatment can help your cancer.

This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.

Do you have ovarian cancer that has come back after your first round of treatment? if so you may be able to participate in a research study to test if MIRV in combination with bevacizumab as maintenance therapy, can help to prevent your cancer from returning or delaying your cancer's return.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

To determine the difference in change in apoptosis between diagnosis and surgery as a function of ruxolitinib treatment versus placebo, among participants with high-risk or premalignant breast conditions.

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.